Literature DB >> 19037227

Activated B cells in autoimmune diseases: the case for a regulatory role.

Stephen M Anderton1, Simon Fillatreau.   

Abstract

B lymphocytes contribute to immunity through organogenesis of secondary lymphoid organs, presentation of antigen to T cells, production of antibodies, and secretion of cytokines. Their roles in autoimmune diseases are complex. Clinical trials have shown that depleting B cells can significantly ameliorate such diseases, underlining the contributions of B cells to pathogenesis. Conversely, B-cell depletion can lead to exacerbation of symptoms in some patients. In mice, B cells can offer protection from chronic autoimmune pathologies. It is important to understand the mechanisms responsible for the distinct roles of B cells in autoimmune diseases, and investigation of these processes could highlight new therapeutic strategies. Here, we review recent progress in our understanding of the suppressive functions of activated B cells in mice, as well as the promising potential of B cells for use as cell-based therapy for experimental autoimmune diseases, and, finally, discuss the possibility of translating this cellular approach to treat human autoimmune diseases.

Entities:  

Mesh:

Year:  2008        PMID: 19037227     DOI: 10.1038/ncprheum0950

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  21 in total

Review 1.  Regulatory B cells in autoimmunity: developments and controversies.

Authors:  Claudia Mauri; Paul A Blair
Journal:  Nat Rev Rheumatol       Date:  2010-09-21       Impact factor: 20.543

Review 2.  Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease.

Authors:  Giovanni Maria Rossi; Rossana Rocco; Eugenia Accorsi Buttini; Chiara Marvisi; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2017-01-09       Impact factor: 3.397

3.  Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.

Authors:  Xiaomei Wang; Babak Moghimi; Irene Zolotukhin; Laurence M Morel; Ou Cao; Roland W Herzog
Journal:  Mol Ther       Date:  2014-03-10       Impact factor: 11.454

4.  B Cell Responses Associated with Vaccine-Induced Delayed SIVmac251 Acquisition in Female Rhesus Macaques.

Authors:  Venkatramanan Mohanram; Thorsten Demberg; Thomas Musich; Iskra Tuero; Diego A Vargas-Inchaustegui; Leia Miller-Novak; David Venzon; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2016-08-17       Impact factor: 5.422

5.  Systemic adverse events following rituximab therapy in patients with Graves' disease.

Authors:  D El Fassi; C H Nielsen; P Junker; H C Hasselbalch; L Hegedüs
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

6.  Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.

Authors:  Elisabeth Calderón-Gómez; Vicky Lampropoulou; Ping Shen; Patricia Neves; Toralf Roch; Ulrik Stervbo; Sascha Rutz; Anja A Kühl; Frank L Heppner; Christoph Loddenkemper; Stephen M Anderton; Jean M Kanellopoulos; Pierre Charneau; Simon Fillatreau
Journal:  Eur J Immunol       Date:  2011-05-25       Impact factor: 5.532

7.  BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats.

Authors:  Shan-shan Song; Bei Huang; Qing-tong Wang; Yu-jing Wu; Jing-jing Fu; Yun-fang Zhang; Yan Chang; Jing-yu Chen; Hua-xun Wu; Di Wang; Ling-ling Zhang; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2013-02-04       Impact factor: 6.150

8.  Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.

Authors:  Ding Chen; Monica Blazek; Sara Ireland; Sterling Ortega; Xiangmei Kong; Anouk Meeuwissen; Ann Stowe; Laura Carter; Yue Wang; Ronald Herbst; Nancy L Monson
Journal:  J Immunol       Date:  2014-10-03       Impact factor: 5.422

Review 9.  In vivo induction of regulatory T cells for immune tolerance in hemophilia.

Authors:  Xiaomei Wang; Cox Terhorst; Roland W Herzog
Journal:  Cell Immunol       Date:  2015-10-09       Impact factor: 4.868

10.  The pursuit of transplantation tolerance: new mechanistic insights.

Authors:  Pawan K Gupta; Christine M McIntosh; Anita S Chong; Maria-Luisa Alegre
Journal:  Cell Mol Immunol       Date:  2019-02-13       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.